Autoimmune Disease News and Research

RSS

Autoimmune Disease is a condition in which the body recognizes its own tissues as foreign and directs an immune response against them.

Gene therapy may help prevent progression of type 1 diabetes

Increasing a specific protein in areas of the pancreas that produce insulin blocks the immune attack that causes type 1 diabetes, researchers reported in the August issue of the Journal of Clinical Investigation, published early online.

7 Jul 2011

Avoidance of routine thyroid testing on pregnant women would have let 80% of cases go undetected

A recent study completed by researchers from Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) demonstrates that BMC conducts a high rate of thyroid function testing in pregnant women.

1 Jul 2011

Macrogenics' Protege Phase 3 clinical study of teplizumab in type 1 diabetes published in The Lancet

MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, announced the publication in The Lancet of results from Protege, a Phase 3 clinical study of teplizumab in type 1 diabetes.

29 Jun 2011

Nimbus Discovery closes $24 million Series A financing

Nimbus Discovery LLC, a biopharmaceutical company using state-of-the-art computational technology to discover novel medicines against exciting but previously inaccessible disease targets, today announced the close of a $24M Series A financing.

28 Jun 2011

EMA acceptance of brentuximab vedotin MAA triggers $5M milestone payment to Seattle Genetics

Seattle Genetics, Inc., today announced that it will receive a $5 million milestone payment under its brentuximab vedotin (ADCETRIS) collaboration with Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

27 Jun 2011

Idera presents IMO-3100 data on preclinical model of arthritis at FOCIS 2011

Idera Pharmaceuticals, Inc. announced today the presentation of IMO-3100 mechanism of action data in a preclinical model of arthritis.

24 Jun 2011

FDA grants Orphan Drug Designation for Accentia's Revimmune to treat two autoimmune diseases

Accentia Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Revimmune, the Company's proprietary system-of-care based on high-dose administration of Cytoxan, for the treatment of two autoimmune disease indications, systemic sclerosis and autoimmune hemolytic anemia.

24 Jun 2011

Reductions in obesity-related medical costs offset cost of gastric banding surgery within 2.25 years

Allergan, Inc. today announced a new study published in the peer-reviewed journal Surgery for Obesity and Related Diseases that found the cost of a gastric banding weight-loss surgery procedure, such as Allergan's LAP-BAND Adjustable Gastric Banding System, was offset by reductions in obesity-related medical costs within 2.25 years for surgery eligible patients with diabetes, and within four years of the procedure for all surgery eligible patients.

23 Jun 2011

Rush scientist receives NIH grant to evaluate whether cinnamon may treat MS

A neurological scientist at Rush University Medical Center has received a grant from the National Institutes of Health (NIH) to evaluate whether cinnamon, a common food spice and flavoring material, may stop the destructive process of multiple sclerosis.

23 Jun 2011

Contaminated cocaine may lead to public health epidemic

Doctors warned of a potential public health epidemic in a recent report on patients in Los Angeles and New York who developed serious skin reactions after smoking or snorting cocaine believed to be contaminated with a veterinary medication drug dealers are using to dilute, or "cut," up to 70% of the cocaine in the U.S.

20 Jun 2011

Seattle Genetics brentuximab vedotin, dacetuzumab clinical data to be presented at ICML 2011

Seattle Genetics, Inc. today announced that data from its brentuximab vedotin and dacetuzumab programs will be presented at the 11th International Conference on Malignant Lymphoma being held June 15-18, 2011 in Lugano, Switzerland.

16 Jun 2011

Seattle Genetics, Millennium ADCETRIS phase I trial data on Hodgkin lymphoma presented at EHA

Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited and Seattle Genetics, Inc., announced today that data on ADCETRIS (brentuximab vedotin) in relapsed or refractory Hodgkin lymphoma patients were featured in an oral presentation at the 16th Congress of the European Hematology Association (EHA) in London.

13 Jun 2011

JDRF, Selecta Biosciences partner to develop type 1 diabetes vaccine

The Juvenile Diabetes Research Foundation (JDRF) and Selecta Biosciences, Inc. announced today that they have established a research collaboration to support Selecta's development of a vaccine technology, which may subsequently help to better treat and potentially prevent type 1 diabetes.

9 Jun 2011

Agensys, Seattle Genetics to co-develop second antibody-drug conjugate for multiple solid tumors

Seattle Genetics, Inc. and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that Seattle Genetics has exercised an option to co-develop a second antibody-drug conjugate (ADC) under the companies' existing ADC collaboration agreement.

9 Jun 2011

Adults with herpes zoster may face higher risk of multiple sclerosis

Taiwanese investigators have found that there can be a significantly higher risk of multiple sclerosis (MS) occurring in the year following a shingles, or herpes zoster, attack.

9 Jun 2011

Clovis, Avila select CO-1686 drug candidate for EGFR Mutant-Selective Inhibitor program

Avila Therapeutics, Inc. a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, announced that it has achieved a significant goal in its alliance with Clovis Oncology, Inc.

9 Jun 2011

Millennium, Seattle Genetics' new brentuximab vedotin trial data presented at ASCO 2011

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today reported updated data from a pivotal trial of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma and a phase II trial in relapsed or refractory systemic anaplastic large cell lymphoma.

7 Jun 2011

Scientists use super microscope to pinpoint body’s immunity ‘switch’

Using the only microscope of its kind in Australia, medical scientists have been able for the first time to see the inner workings of T-cells, the front-line troops that alert our immune system to go on the defensive against germs and other invaders in our bloodstream.

5 Jun 2011

New approach for identifying 'self' proteins targeted in autoimmune diseases

Researchers from Harvard Medical School and MIT have developed a new approach for identifying the "self" proteins targeted in autoimmune diseases such as multiple sclerosis, diabetes and rheumatoid arthritis.

3 Jun 2011

Green tea consumption increases number of 'regulatory T cells', prevents autoimmune disease

One of the beneficial compounds found in green tea has a powerful ability to increase the number of "regulatory T cells" that play a key role in immune function and suppression of autoimmune disease, according to new research in the Linus Pauling Institute at Oregon State University.

3 Jun 2011

Autoimmune Disease News and Research

Further Reading

Gene therapy may help prevent progression of type 1 diabetes

Avoidance of routine thyroid testing on pregnant women would have let 80% of cases go undetected

Macrogenics' Protege Phase 3 clinical study of teplizumab in type 1 diabetes published in The Lancet

Nimbus Discovery closes $24 million Series A financing

EMA acceptance of brentuximab vedotin MAA triggers $5M milestone payment to Seattle Genetics

Idera presents IMO-3100 data on preclinical model of arthritis at FOCIS 2011

FDA grants Orphan Drug Designation for Accentia's Revimmune to treat two autoimmune diseases

Reductions in obesity-related medical costs offset cost of gastric banding surgery within 2.25 years

Rush scientist receives NIH grant to evaluate whether cinnamon may treat MS

Contaminated cocaine may lead to public health epidemic

Seattle Genetics brentuximab vedotin, dacetuzumab clinical data to be presented at ICML 2011

Seattle Genetics, Millennium ADCETRIS phase I trial data on Hodgkin lymphoma presented at EHA

JDRF, Selecta Biosciences partner to develop type 1 diabetes vaccine

Agensys, Seattle Genetics to co-develop second antibody-drug conjugate for multiple solid tumors

Adults with herpes zoster may face higher risk of multiple sclerosis

Clovis, Avila select CO-1686 drug candidate for EGFR Mutant-Selective Inhibitor program

Millennium, Seattle Genetics' new brentuximab vedotin trial data presented at ASCO 2011

Scientists use super microscope to pinpoint body’s immunity ‘switch’

New approach for identifying 'self' proteins targeted in autoimmune diseases

Green tea consumption increases number of 'regulatory T cells', prevents autoimmune disease

Understanding the DNA Damage Response in Innate Immunity eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News